Literature DB >> 32886809

Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.

Jordi Rimola1,2, Agnès Fernàndez-Clotet2,3, Nunzia Capozzi1,4, Sònia Rojas-Farreras5, Ignacio Alfaro3,6, Sonia Rodríguez1, Maria-Carme Masamunt3,7, Elena Ricart2,3,7,8, Ingrid Ordás2,3,7,8, Julian Panés2,3,7,8.   

Abstract

BACKGROUND: Identifying predictors of therapeutic response is the cornerstone of personalised medicine. AIM: To identify predictors of long-term healing of severe inflammatory lesions based on magnetic resonance enterography (MRE) findings in patients with Crohn's disease (CD) treated with tumour necrosis factor alpha (TNF-α) inhibitors.
METHODS: This prospective longitudinal single-centre study included patients with clinically active CD requiring treatment with TNF-α inhibitors with at least one intestinal segment with a severe inflammatory lesion detected by MRE (segmental MaRIA ≥11). MRE data were obtained at baseline, and at weeks 14 and 46. The primary endpoint was healing of severe inflammatory lesions (MaRIA <11) in each segment. The secondary endpoint was healing of all severe inflammatory lesions on a per-patient analysis.
RESULTS: We included 58 patients with 86 intestinal segments with severe inflammatory lesions. At week 46, healing of severe lesions was found in 51/86 (59.3%) segments, and complete healing of inflammatory lesions in all segments was found in 28/58 (48.6%) patients. Multivariable analysis found baseline-negative predictors of long-term healing of severe inflammation were ileal (as opposed to colonic) location (OR 0.00, [0.00-0.56] P = 0.002) and presence of creeping fat on MRE (OR 0.00 [0.00-0.57]; P = 0.001). Persistence of segmental MaRIA score >10.6 at week 14 was a negative predictor of healing at week 46 (OR 0.3 [0.04--0.38]; P < 0.001).
CONCLUSION: In patients with CD, the absence of creeping fat detected at baseline MRE and location of severe inflammatory lesions are clinically relevant predictors of long-term healing of severe inflammation under treatment with TNF-α inhibitors.
© 2020 John Wiley & Sons Ltd.

Entities:  

Year:  2020        PMID: 32886809     DOI: 10.1111/apt.16069

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity.

Authors:  Agnès Fernàndez-Clotet; Víctor Sapena; Nunzia Capozzi; Sonia Rodríguez; Maria-Carme Masamunt; Elena Ricart; Ingrid Ordás; Julian Panés; Jordi Rimola
Journal:  Eur Radiol       Date:  2022-01-15       Impact factor: 5.315

2.  A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn's disease patients treated with infliximab.

Authors:  Chao Zhu; Jing Hu; Xia Wang; Cuiping Li; Yankun Gao; Jianying Li; Yaqiong Ge; Xingwang Wu
Journal:  Eur Radiol       Date:  2022-07-20       Impact factor: 7.034

3.  Association of Baseline Luminal Narrowing With Ileal Microbial Shifts and Gene Expression Programs and Subsequent Transmural Healing in Pediatric Crohn Disease.

Authors:  Allison D Ta; Nicholas J Ollberding; Rebekah Karns; Yael Haberman; Adina L Alazraki; David Hercules; Robert Baldassano; James Markowitz; Melvin B Heyman; Sandra Kim; Barbara Kirschner; Jason M Shapiro; Joshua Noe; Maria Oliva-Hemker; Anthony Otley; Marian Pfefferkorn; Richard Kellermayer; Scott Snapper; Shervin Rabizadeh; Ramnik Xavier; Marla Dubinsky; Jeffrey Hyams; Subra Kugathasan; Anil G Jegga; Jonathan R Dillman; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2021-10-20       Impact factor: 5.325

4.  Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease.

Authors:  Kerri L Novak; Kim Nylund; Christian Maaser; Frauke Petersen; Torsten Kucharzik; Cathy Lu; Mariangela Allocca; Giovanni Maconi; Floris de Voogd; Britt Christensen; Rose Vaughan; Carolina Palmela; Dan Carter; Rune Wilkens
Journal:  J Crohns Colitis       Date:  2021-04-06       Impact factor: 9.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.